A Partnership to Study Biomarkers of Dementia in Down syndrome

A public–private partnership to establish biomarkers of dementia in Down’s syndrome could aid the development of preventive therapies for the dementia associated with both Down’s syndrome and Alzheimer’s disease, based on the apparent common pathogenic role of amyloid precursor protein in the two conditions. Learn more in the journal, Nature. To obtain a copy of this paper, you need only register on the Nature website.This work is ongoing as a collaborative effort with RDS grantee, the University of California San Diego Down Syndrome Research and Treatment Center

A public–private partnership to establish biomarkers of dementia in Down syndrome could aid the development of preventive therapies for the dementia associated with both Down’s syndrome and Alzheimer’s disease, based on the apparent common pathogenic role of amyloid precursor protein in the two conditions. Learn more in the journal, Nature. To obtain a copy of this article, you need only register on the Nature website.

This work is ongoing as a collaborative effort which includes RDS grantee, the University of California San Diego Down Syndrome Research and Treatment Center.